Selected Publications: 


  1. Rahat MA, Galdiero MR. (eds) Extracellular Traps in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2023 (eBook)
  2. Rahat MA, Iragavarapu-Charyulu V, Kzhyshkowska J. (eds). Targeting Angiogenesis to Treat Autoimmune Diseases and Cancer. Frontiers in Immunology, pp. 1-117, 2020 (eBook), Lausanne: Frontiers Media SA. doi: 10.3389/978-2-88963-827-7.
  3. Rahat MA, Coffelt SB, Granot Z, Muthana M, and Amedei A. (eds.) Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer. Mediators of Inflammation, 2016 (eBook).
  4. Rahat MA, Hemmerlein B, and Iragavarapu-Charyulu V. (eds.). The regulation of angiogenesis by tissue cell-macrophage interactions. Frontiers in Physiology, 2014 (eBook).



  1. Rahat MA.  Mini Review: Can the metastatic cascade be inhibited by targeting CD147/EMMPRIN to prevent tumor recurrence? Frontiers in Immunology, 2022; 13:855978
  2. Rahat MA. Targeting angiogenesis with peptide vaccines. Frontiers in Immunology, 2019; 10: Article 1924
  3. Rahat MA. Targeting angiogenesis with peptide vaccines. Frontiers in Immunology, 10: Article 1924, 11 pages, 2019
  4. Rahat MA and Shakya J. Parallel aspects of the microenvironment in cancer and autoimmune diseases. Mediators of Inflammation, vol. 2016; Article ID 4375120,  2016
  5. Rahat MA and Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Frontiers in Vascular Physiology 2013; 4:144 
  6. Rahat MA, Bitterman H, Lahat N. Molecular Mechanisms Regulating Macrophage Response to Hypoxia. Frontiers in Immunology 2011; 2:45 

The tumor microenvironment, targeting EMMPRIN/CD147

  1. Feigelman G*, Simanovich E*, Brokmeyer P, Rahat MA. Knocking-down CD147/EMMPRIN expression in CT26 colon carcinoma forces the cells into cellular and angiogenic dormancy that can be reversed by interactions with macrophages. Biomedicines 2023; 11, 768.
  2. Khromov T, Fischer L, Leha A, Bremmer F, Fischer A, Schliephake H, Rahat MA, Brockmeyer P. Combined biomarker system predicts prognosis in patients with metastatic oral squamous cell carcinoma. Cancers, 2023: 15: 4924
  3. Schminke B, Shomroni O, Salinas G, Bremmer F, Kauffmann P, Schliephake H, Oyelami F, Rahat MA, Brockmeyer P. Prognostic factor identification by screening changes in differentially expressed genes in oral squamous cell carcinoma. Oral Diseases, 2021 29(1):116-127.
  4. Hijaze N, Ledersnaider M, Simanovich E, Kassem S, and Rahat MA. Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody 161-pA and complement factors. Journal of Leukocyte Biology, 2021; 10: 343-356.
  5. Simanovich E, Brod V, Rahat MM, Rahat MA. Function of miR-146a-5p in tumor cells as a regulatory switch between death and angiogenesis: macrophage therapy revisited. Frontiers in Immunology, 2018; 8:1931
  6. Simanovich E, Brod, V, Rahat MA. Targeting EMMPRIN by vaccinating with a multiple antigenic peptide (161-MAP) reduces angiogenesis in a dextran sodium sulfate (DSS)-induced colitis model. Frontiers in Immunology, 2018; 9: 2919,13 pages
  7. Simanovich E, Brod V, Rahat MA. Active Vaccination With EMMPRIN-Derived Multiple Antigenic Peptide (161-MAP) Reduces Angiogenesis in a Dextran Sodium Sulfate (DSS)-Induced Colitis Model.  Front Immunol. 2018 Dec 10;9:2919.
  8. Simanovich E, Brod V, Rahat MM, Rahat MA. Function of miR-146a-5p in Tumor Cells As a Regulatory Switch between Cell Death and Angiogenesis: Macrophage Therapy Revisited. Front Immunol. 2018 Jan 5;8:1931.
  9. Simanovich E, Brod V, Rahat MM, Drazdov E, Walter M, Shakya J, and Rahat MA. Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation. Oncoimmunology 2017; 6(1), e1261778.
  10. Walter M, Simanovich E, Brod V, Lahat N, Bitterman H, and Rahat MA. An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression. Oncoimmunology 2016; 5(2), e1078056.
  11. Amit-Cohen BC, Rahat MM, Rahat MA. Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN. Frontiers in Vascular Physiology 2013; 4:178
  12. Perske C, Lahat N, Sheffy Levine S, Bitterman H, Hemmerlein B, Rahat MA.  Loss of inducible nitric oxide synthase (iNOS) expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. Am. J. Pathol. 2010; 177(4): 2046-54

EMMPRIN/CD147 and angiogenesis in RA and PsA

  1. Zisman D, Sabtan H, Rahat MM, Simanovich E, Haddad A, Gazitt T, Slobodin G, Kibari A, Elias M, Rahat MA. Tofacitinib regulates Endostatin via its effects on CD147 and cathepsin S. (2023, In preparation)
  2. Rahat MM, Sabtan H, Simanovich E, Haddad A, Gazitt T, Slobodin G, Kibari A, Elias M, Zisman D*, and Rahat MA*. Soluble CD147 regulates Endostatin expression and activity via its effects on the regulation of MMP-9 and secreted proteasome 20S activities. (2023, Submitted).
  3. Zisman D, Safieh M, Simanovich E, Feld J, Kinarty A, Zisman L, Gazitt T, Haddad A, Elias M, Rosner I, Kaly L, Rahat MA. Tocilizumab (TCZ) decreases angiogenesis in Rheumatoid Arthritis through its regulatory effect on miR-146a-5p and EMMPRIN/CD147. Frontiers in Immunology 2021; 12: 739592
  4. Rahat MA, Safieh M, Simanovich E, Pasand E, Gazitt T, Haddad A, Elias M, Zisman D.  The role of EMMPRIN in regulating angiogenesis in patients with psoriatic arthritis. Arthritis Research and Therapy, 2020; 22: 240-252
  5. Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, Lavie I, Gazitt T, Zisman D. Effects of Tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int. J. Mol. Sci. 2019; 20(18): 4633-4644.

Effect of hypoxia on macrophages

  1. Lahat N, Bitterman H, Weiss-Cerem L, Rahat MA. Hypoxia increases the membranal and secreted forms of HLA-DR in endothelial cells and renders them capable of activating T cells. Transplat. Int. 2011; 24(10):1018-26
  2. Lahat N, Bitterman H, Engelmayer-Goren M, Rosenzweig D, Weiss-Cerem L, Rahat MA. Reduced TIMP-2 in hypoxia enhances angiogenesis. Am. J. Physiol. Cell physiol. 2011; 300(3): C557-C566
  3. Lahat N, Rahat MA, Kinarty A, Weiss-Cerem L, Pinchevski, S, Bitterman H. Hypoxia enhances lysosomal TNFα degradation in peritoneal mouse macrophages.  Am. J. Physiol. Cell Physiol. 2008; 295(1): C2-C12
  4. Marom B, Rahat MA, Lahat N, Bitterman H. Native and fragmented fibronectin oppositely modulate monocyte expression of MMP-9. J. Leukocyte. Biol. 2007; 81(6):1466-1476
  5. Rahat MA, Marom B, Bitterman H, Lahat N. Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocyte by inhibiting its secretion and elevating membranal association. J. Leukocyte. Biol. 2006; 79(4): 706-718
  6. Daniliuc S, Bitterman H, Rahat MA, Kinarty A, Rosenzweig D, and Lahat N. Hypoxia inactivates inducible nitric oxide synthase in mouse macrophages by disrupting its interaction with α-actinin 4. J. Immunol. 2003; 171(6): 3225-3232
  7. Lahat N, Rahat MA, Ballan M, Weiss-Cerem L, Engelmayer M, and Bitterman H. Hypoxia reduces CD80 expression on monocytes, but enhances their LPS-stimulated TNFα secretion. J. Leukocyte. Biol.  2003; 74(2): 197-205


  1. 2012 Rahat MA, Lahat N, Bitterman H, Walter M. Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies; PCT Patent Application No. PCT/IL2013/050231; International Publication Number: WO 2013/150518 A1. US Grant US9688732B2; US application US20170247422A1; EP application EP2833900A4.
  2. 2023    Rahat MA, Simanovich E. Monoclonal Antibodies Targeting the Human CD147/EMMPRIN protein. PCT patent application No. 63/426,796.